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1. Introduction 
The majority of plasma proteins are modified by the addition of oligosaccharide chains 
(glycans) to their surface. The process, known as glycosylation, is responsible for 
introducing huge structural variation and is important in the determination of functional 
properties expressed by the overall glycoprotein. Glycan composition and structure can 
vary widely, potentially showing disease- specificity, unlike the underlying polypeptide 
sequence [1-3]. Therefore analysis of their structures could offer more accurate and 
condition-specific markers which is critical when early treatment and monitoring is crucial 
in tackling diseases. The monomeric units of glycans are the monosaccharides, linked 
together via glycosidic bonds between the –OH reducing group of C1 and any other –OH of 
adjacent residues (a condensation reaction). The bonds exist in either an α or β anomeric 
configuration, depending on the orientation of the bond, providing further opportunity to 
generate structural variability. 
Unlike the structure of the polypeptide backbone, glycosylation is not directly encoded by 
specific genes, but is reliant upon the concerted action of a series of highly specific enzymes 
(glycosyltransferases and glycosidases), which are resident in the ER and Golgi of cells, to 
initiate and processing glycan chain precursors. Any alterations in the expression of the genes 
encoding these enzymes due to, for example a pathophysiological condition, will affect the 
structure and composition of the glycans generated. During the synthesis and processing of 
glycans, they are transferred by the enzyme oligosaccharyltransferase from a lipid-linked 
oligosaccharide donor to polypeptide chains, either at asparagine (N-linked) or 
Serine/Threonine (O-linked) residues. N-linked glycans share a common pentasaccharide core 
(Man3GlcNAc2), however the overall structures can vary widely, primarily differing by the 
sequence and quantity of monosaccharides of which they are composed. Glycan synthesis then 
proceeds by the sequential addition/removal of individual monosaccharide units.  
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Glycan expression is cell and tissue specific and dependent on the presence of (patho)-
physiological conditions [4]. Abnormal expression of even a single enzyme participating in 
this process may alter the subsequent steps and give rise to aberrant oligosaccharide 
structures. The cell types containing these biomolecules determine the enzymes expressed 
and therefore the glycans – variation reflects these source cells or tissue and the 
physiological and biochemical conditions present [3-4]. For example, abnormal or unusual 
glycan moieties are often detected on the surface of tumour cells, as well as among secreted 
glycoproteins. Many well known tumour-associated antigens are glycolipids or 
glycoproteins that contain aberrant glycan structures [5].  
The post translational modification of proteins with oligosaccharide chains offers several 
advantages as a potential source of cancer biomarkers [5-6]. While protein biomarkers 
frequently occur in low abundance, distinctive cellular glycan structures, including those 
that are tumour-specific, are typically fairly abundant. Such structures are usually 
synthesised in multiple copies on a single glycoprotein molecule. In addition, the same 
tumour-specific glycan structures may be present on several different glycoproteins. 
Importantly, many currently used biomarker molecules, such as prostate specific antigen, 
CA125, and carcinoembryonic antigen, are monitored solely based on protein levels, not on 
their tumour-specific glycan moieties.  
Glycoproteins with modified glycosylation resulting from the presence of cancer may be 
identifiable in body fluids that are typically amenable for clinical testing [6]. Alpha – 1 (or 
α1) – acid glycoprotein (AGP, or orosomucoid) is an important example of a naturally 
occurring N-linked plasma glycoprotein secreted by liver parenchymal cells. It was first 
isolated and characterised in the 1950s and although its specific biological role/function has 
yet to be clearly defined it is considered a natural anti-inflammatory and 
immunomodulatory agent [7-9], the concentration and/or ‘normal’ glycosylation of which 
may change under various physiological and pathophysiological conditions. It is a highly 
glycosylated (45%) protein and therefore investigations into alterations in its glycan profile 
during different diseases has been, and is still, of great interest (Figure 1). Sialic acid, in the 
form of N-acetylneuraminic acid (NeuAc), accounts for 12% of the total number of 
monosaccharides, and is responsible for giving AGP its low isoelectric point of 2.7.  
Alterations in the protein levels of AGP have been well documented for numerous 
physiological and pathophysiological conditions including lung and breast cancer [10] and 
malignant mesothelioma [11]. It has been suggested that a marked increase in AGP 
concentration may limit adverse reactions such as inflammation by providing a form of 
negative feedback [12]. Increased concentrations are associated with expression of the ORM-
1 and ORM-1 genetic variants of AGP; however the proportions of each do not necessarily 
differ to that of a healthy individual [10]. In terms of plasma concentration, increased levels 
of AGP have been detected in the plasma of patients with breast cancer [13] and have also 
been shown to increase with disease progression [14] but to return to normal upon 
treatment with tamoxifen [15]. This indicates that the prognosis of breast cancer appears to 
be linked to the APR in general and AGP levels in particular. Not only is there a dearth of 
studies determining the levels of AGP in breast cancer but more importantly there has been 
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no investigations of the glycosylation of AGP in breast cancer, the extent that it is altered 
and/or its significance as a diagnostic marker. 
 
Figure 1. General schematic illustrating the structure of alpha-1-acid glycoprotein. 
Although the concentration of AGP alone is not diagnostic for a particular pathological 
condition, the altered glycosylation of AGP (microheterogeneity) in different diseases, 
provides an alternative biomarker target. These alterations have the potential to be markers 
for particular diseases and also disease progression. The major form of heterogeneity, type I, 
is associated with a reduction in the number of branches on the oligosaccharide chains [4, 
16-17]; the minor form (type II) concentrates on the composition of the oligosaccharide 
chains namely the extent of fucosylation and sialylation of the five oligosaccharide chains 
[18].  
There is potential for the existence of 105 different glycoforms of AGP due to the huge 
structural variability provided mainly by the presence of glycans. However in normal, non-
pathological conditions there are only 12-20 expressed, each exhibiting various degrees of 
branching, fucosylation and sialylation [18]. The number of feasible glycoforms is reduced 
because the asparagines (Asn) residues are selective for the type of glycans they express in 
terms of the degree of branching. The first and second Asn sites (Asn 15 and 38) prefer to 
harbour bi-antennary glycans whilst Asn 15 will not bind a tetra-antennary chain and Asn 
38 never binds fucosylated glycans. Conversely, Asn 75 and Asn 85 prefer more branched 
glycans; in fact site Asn 75 never carries bi-antennary chains and Asn 85 usually expresses 
the greatest degree of α1,3-fucosylation [16]. This increased branching could explain why 
only these two sites potentially carry a tetra-antennary chain with more than one fucose 
residue [8]. It has been found that the majority of AGP glycans have a tri/tetra-antennary 
structure (85-90%) and the remaining 10-15% is bi-antennary glycans [19]. Sialic acid can be 
bound α2-3 or α2-6 on terminal galactose residues; fucose can be bound α1-3 to an external 
N-acetlyglucosamine and also by α1-6 and α1-2 to core N-acetlyglucosamine and galacose 
residues respectively [8]. The extent of fucosylation in a healthy population varies with 30% 
[8] to 40% [20] containing no fucose.  
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Altered glycosylation of AGP has been widely studied in a number of pathophysiological 
conditions. Decreased branching of the five glycans of AGP has been demonstrated in acute 
inflammation while an increase is associated with chronic inflammation [21-23]. Chronic 
inflammatory states such as those found in patients with RA are characterised by an 
increase in branching [24, 25], increased fucosylation of the chains [26-31] and increased 
sialic acid content [32-33]. The expression of the antigen sialyl lewis X (SLeX ) has been found 
to increase on AGP oligosaccharides [20, 25-26] at any one of the 5 sites of glycosylation [27]. 
SLeX is normally expressed on white blood cells and aids through binding to the endothelial 
ligand, E-Selectin, the extravasation of leukocytes into tissues to mount their inflammatory 
response. De Graaf and colleagues [20] proposed that the increased expression of this 
antigen on AGP represents a negative feedback response during inflammatory conditions. 
Further work by Jørgensen et al. [26] using a microtitre cell-protein binding assay discovered 
that SLeX-containing AGP expressed in patients with RA was able to inhibit binding of SLeX 
presenting cells to E-Selectin. Thus, during inflammatory states such as those in RA, the 
abnormally glycosylated form of AGP has the ability to competitively bind to E-Selectin and 
inhibit leukocyte extravasation exerting an overall anti-inflammatory effect. Highly 
branched structures have also been noted in individuals with liver disease, along with 
increased fucosylation of these chains [34-36]. Increased concentrations of AGP were found 
in the cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS) compared to disease 
free individuals [37] and in the plasma/serum of patients with burns injuries [38]. It is 
known that various factors act to influence AGP glycosylation including the congentital 
disorders [28], pregnancy [29, 33], drug or glucocorticoid use [39], and oral contraceptive 
use [40]. 
Investigations into the heterogeneity of AGP in cancer have found an increase in bi-
antennary glycan content with increased fucosylation and sialylation. An early study by [41] 
reported that the major microheterogeneity of AGP from malignant, benign and normal 
groups was significantly different from each other. When compared with normal controls, 
sera from patients with inflammatory lung disease (benign group) exhibited an increase in 
tri-and tetra-antennary glycans and in sera from lung cancer patients (malignant group) 
there was an increase in bi-antennary expression. This work was contradicted the following 
year in an investigation [42] which repeated the study including an evaluation of the 
microheterogeneity of AGP in colorectal cancer and reported that there was no significant 
difference in the microheterogeneity of AGP from malignant and non-malignant 
inflammatory disease. Evidence to support the cancer-induced expression of bi-antennary 
glycans on AGP detailed by Hansen and colleagues was provided by [43] who reported a 
similar finding on AGP from the ascitic fluid of liver cancer patients.  
Reports of changes in the minor microheterogeneity of AGP from studies of the 
oligosaccharide content of the chains in cancer have been detailed. Early studies [44-45] 
observed an increase in the sialic acid content of cancer AGP glycans compared to normal 
controls. A more recent study by Hashimoto et al. [46] on AGP branching and fucosylation 
in cancer concluded that changes in microheterogeneity could be used as a marker of 
carcinoma progression and prognosis. Patients with advanced stages of the disease who 
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displayed highly branched glycans with a high fucose content for a significant duration 
post-surgery were associated with poor prognosis whereas, patients who did not display 
this increase in branching and fucosylation were likely to have a good, more reassuring 
prognosis. When highly branched and fucosylated glycans were present a prolonged period 
after surgery, a poor prognosis was associated. Similar analyses can be associated with 
surgery and other traumas in general [47]. 
2. Problem statement 
The majority of studies [reviewed in 7-9] have concluded that, although increased levels of 
AGP have been detected in the plasma of patients with breast cancer, this concentration is 
largely unrelated to disease progression. The prognostic value of AGP glycosylation in 
breast cancer is still largely unproven. Although the limited research to date has discovered 
structural differences in the glycosylation in AGP isolated from different cancers and early 
and advanced stages of the same cancer, very few studies have looked at breast cancer 
samples. We hypothesise that alpha-1-acid glycoprotein (AGP), which is a common 
constituent in all blood, could be a diagnostic marker for early breast cancer.  
3. Application area 
There is a critical need for information regarding a reliable biomarker that could be used to 
predict the onset, severity, progression and prognosis of breast cancer. The identification of 
alterations in AGP glycosylation specific to individual stages of breast cancer could, through 
being altered to the “normal” healthy AGP glycosylation pattern, result in the development 
of a diagnostic test based on AGP glycosylation for the onset, progression and/or prognosis 
of breast cancer. 
4. Aims of study 
To determine whether specific alterations in the glycosylation pattern of alpha-1-acid 
glycoprotein (AGP) could be diagnostic for the for the onset, progression and/or prognosis 
of breast cancer. 
5. Study design and methodology (Figure 2) 
5.1. Patient samples 
Breast cancer can occur as a non-malignant or malignant tumour. Non-malignant cancers 
can be further subdivided into ductal carcinoma in situ (DCIS) and lobular carcinoma in situ 
(LCIS). In situ refers to the state and location of the breast epithelial cells in that they have 
gone through malignant transformation and are now proliferating but remain at the site of 
origin and do not penetrate the basement membrane into surrounding tissues. DCIS and 
LCIS are not at risk of metastatic spread as there are no blood vessels or lymphatics in the 
epithelial layer of the breast [48]. The two most common types of invasive or malignant 
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breast cancer are Invasive ductal carcinoma (IDC) and Invasive lobular carcinoma (ILC). 
Approximately 75% of breast cancers are IDC with ILC accounting for a further 10%. The 
remaining 15% of diagnosed invasive breast cancers are made up of rare types such as 
mucinous, medullary, tubular, and papillary. Blood samples were taken from non-fasting 
patients with consent by Calgary Laboratory Services. The blood samples were drawn into 
5mL Red Top tubes and processed within 30 minutes. During processing, the blood samples 
were spun for 30 minutes to separate them into components. The samples were stored at -80 
degrees Celsius. The patient details are given in Table 1. 
 
Figure 2. The design of the study to determine the glycosylation patterns of AGP in breast cancer  
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No Age Description Her2 Malignant. Grade ER 
1 62 Benign proliferative breast disease N/A No . . 
2 78 DCIS (+ invasive ductal carcinoma) neg. Yes 3.00 . 
3 48 Benign proliferative breast disease N/A No . . 
4 77 Invasive duct carcinoma neg. Yes 1.00 1.00 
5 51 Invasive duct carcinoma neg. Yes 2.00 1.00 
6 35 Invasive duct carcinoma neg. Yes 1.00 1.00 
7 39 Benign proliferative breast disease N/A No . . 
8 35 Malignant phyllodes tumor. neg. Yes . . 
9 53 DCIS (+ invasive ductal carcinoma) neg. Yes . . 
10 49 Invasive duct carcinoma pos. Yes 2.00 1.00 
11 76 Invasive duct carcinoma neg. Yes 2.00 1.00 
12 65 Invasive duct carcinoma neg. Yes 3.00 1.00 
13 32 Invasive ductal carcinoma pos. Yes . . 
14 43 Invasive duct carcinoma neg. Yes 3.00 1.00 
15 40 Biphasic fibroepithelial lesion N/A No . . 
16 48 Benign proliferative breast disease N/A No . . 
17 50 Invasive duct carcinoma pos. Yes 3.00 1.00 
18 69 Invasive duct carcinoma neg. Yes 2.00 . 
19 45 Invasive duct carcinoma pos. Yes 3.00 .00 
Table 1. Demographic and clinical details of patients used in study 
5.2. Materials 
5.2.1. AGP Isolation 
Polyethylene glycol (PEG 3350), the low pressure chromatographic material (Cibacron Blue 
3GA, Q-sepharose and Red Sepharose CL-6B), potassium thiocyanate, sodium acetate, 
sodium chloride and Trizma base were purchased from Sigma (Poole, UK). Bio-Rad, Hemel 
Hampstead, UK, provided the poly-prep disposable 10ml columns. HPLC-grade water and 
the Centricon YM10 centrifugal filter device were purchased from Rathburn Chemicals 
(Walkerburn, UK) and Millipore (Bedford, USA) respectively. 
5.2.2. High pH anion exchange chromatography monosaccharide analysis 
HPAEC was carried out on a DX600 system supplied by Dionex (Camberley, UK), 
consisting of a GP50 gradient pump and an ED40 electrochemical detector, controlled with 
PeakNet software via a Dell OptiPlex GX110 personal computer. Separation of 
monosaccharides was achieved using a CarboPac PA-100 (250x4mm) and guard column 
(50x4mm). HPLC grade water was purchased from Rathburn Chemicals, Walkerburn, UK, 
and sodium hydroxide 50% w/v was obtained from BDH, Poole, UK. The monosaccharide 
standards and Dowex-50W were purchased from Sigma, Poole, UK. HPLC grade 
trifluoroacetic acid was purchased from Perbio Science, UK Ltd, Talenhall, UK. 
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5.2.3. Oligosaccharide analysis 
PNGase F and buffers (NP40 and NE buffer G7) were supplied by New England BioLabs 
(New England, USA). HPAEC was carried out on a DX500 system supplied by Dionex 
(Camberley, UK), consisting of a GP40 gradient pump and an ED40 electrochemical 
detector, controlled with PeakNet software via a Vtech personal computer. Separation of 
monosaccharides was achieved using a CarboPac PA-100 (250x4mm) and guard column 
(50x4mm). HPLC grade water was purchased from Rathburn Chemicals, Walkerburn, UK, 
and sodium hydroxide 50% w/v was obtained from BDH, Poole, UK. Sodium acetate was 
purchased from Sigma (Poole, UK). 
5.3. Methods 
5.3.1. Polyethylene Glycol (PEG) precipitation 
First, PEG 3350 was added to each plasma sample to a final concentration of 40% w/v in a 
microcentrifuge tube. This was then mixed vigorously for ten minutes before being stored 
overnight at 4ºC. Subsequently the mixture was centrifuged at 14,000 rpm for 30minutes. 
The supernatant was removed to a clean eppendorf and frozen until required, with the 
pellet being discarded. 
5.4. Low pressure chromatography to isolate AGP 
A disposable BioRad low-pressure chromatography column (10ml) was packed to a bed 
volume of approximately 6ml with the appropriate chromatographic resin. Several volumes 
of the appropriate Elution buffer (Table 2) was washed through the column using a 
Pharmacia LKB peristaltic pump at a flow rate of 0.5ml/min, with the change in UV 
absorbance at 280nm being detected using a Pharmacia LKB optical unit. Peak fractions 
were collected in 15ml disposable centrifuge tubes and dried under vacuum to 
approximately 2ml between stages, using a centrifugal evaporator. 2-3ml of the PEG-
precipitated serum sample is first applied to a Cibacron blue column, to which the bilirubin 
site of albumin binds. The remaining soluble proteins are eluted with 0.05M Tris/0.1M 
potassium chloride/0.02% Azide (pH7.0) elution buffer while the albumin is removed from 
the column with 0.5M potassium thiocyanate. One peak is collected upon elution. After 
drying the peak is next applied to the ion-exchange column Q-sepharose. This divides the 
eluate from the previous column into three fractions; α1-antitrypsin, AGP and transferrin. A 
column gradient of 0.075-0.5M sodium chloride (pH 6.5) is utilised, and the second peak, 
which contains AGP, is collected. The column is regenerated between samples by washing 
the column with 0.075M NaCl buffer until a flat baseline is observed. The AGP is then, after 
again drying to 2-3ml, applied to a column containing the Red sepharose resin in order to 
remove any trace proteins that may remain. The AGP in the sample is eluted with a 0.03M 
sodium acetate elution buffer and collected, while the bound proteins are removed with 1M 
sodium chloride. The AGP peak is then dried to 2ml in preparation for desalting. 
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 Buffer
Chromatography resin Elution Desorption
Cibacron Blue 
50mM Trizma/0,1mM 
KCl/0.02% Azide at pH 7.0 
500mM KSCN/50mM 
Trizma/0.1mM KCl/0.02% 
Azide pH 7.0 
Q-sepharose fast flow 
20mM Trizma/75mM NaCl 
pH6.5 
Equilibrium buffer: 20mM 
Trizma/75mM NaCl pH 6.5 
Red sepharose CL-6B 30mM NaOAc 1M NaCl/30mM NaOAc 
Table 2. Buffers for each stage of low-pressure chromatography  
5.5. Desalting 
In The AGP peak from red sepharose was subsequently desalted using centrifugal 
ultrafiltration. 2mL of the sample was added to a Centricon centrifugal filter device. This 
removes any salt in the solution and also acts to concentrate the AGP. The centricons were 
spun at 4000 rpm until the filtrate had passed entirely through the membrane into the 
filtrate vial. To ensure complete removal of salt from the sample 1ml of HPLC water was 
added to the sample reservoir and spun as before. The centricon was then inverted and spun 
for 10 minutes at 1000 rpm, transferring the concentrate into the collection vial. The desalted 
glycoprotein is then transferred to an eppendorf and dried down to completion using a 
centrifugal evaporator. 
5.6. High pH Anion Exchange Chromatography (HPAEC) 
5.6.1. Preparation of monosaccharides: Acid Hydrolysis of AGP 
Approximately 50µg of isolated AGP was hydrolysed using 100µl 2M trifluoroacetic acid 
(TFA) and 50µl 4M hydrochloric acid in a reacti-vial then sealed with a Teflon disc. The 
reacti-vial was then placed on a heating block pre-heated to 100ºC for four hours in order to 
reach optimum hydrolysis. The monosaccharides were separated from the peptide 
fragments by eluting the hydrolysate down a Dowex-50W cation exchange column. A 
Pasteur pipette was plugged with glass wool and loaded with the resin to a bed volume of 
1ml. Each AGP sample was added to a separate column and washed through with HPLC 
water. The neutral monosaccharides were washed through and collected, then dried to 
completion in preparation for analysis. 
5.6.2. Monosaccharide analysis 
Monosaccharide analysis was carried out using a DX600™ system. Separation of the 
monosaccharides, as their oxyanions, was performed at pH 13 on a CarboPac PA-100 
column. The monosaccharides were resolved using an isocratic elution with 30mM  
NaOH, at a flow rate of 0.5ml/min for 35 minutes. The column was regenerated after each 
run with 0.5M NaOH for 5 minutes, prior to equilibration with 20mM NaOH for a further  
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10 minutes. Detection of monosaccharides was by pulsed amperometric detection (PAD)  
at the following pulse potentials: 0 sec: E=0.05V; 0.29sec: E=0.05V; 0.49sec: E=0.05V;  
0.50sec: E=0.05V; 0.51sec: E=0.6V; 0.6sec: E=0.6V; 0.61sec: E=-0.6V; 0.65sec: E=-0.6V; 0.66sec: 
E=0.05V (Figure 3). 
 
 
 
 
Figure 3. The triple pulsed waveform used in pulsed amperometric detection 
An internal standard (IS) of 2-deoxy-D-galactose was utilised to determine the elution 
position of the monosaccharides by dividing the elution time of the IS by the time of the 
unknown peak. The calculated ratio can then be compared to known standards. 
5.6.3. HPAEC-PAD oligosaccharide analysis 
The required amount (50-100µg) of AGP was reconstituted in 100 µL of HPLC grade water. 
The AGP solution was subsequently denatured through boiling for one hour. To the 
denatured AGP 10 µL of NP-40, 10 µL of NE Buffer G7 and 100U of PNGase F were added. 
PNGaseF cleaves the oligosaccharide chains from the AGP peptide moiety. The enzymatic 
reaction was allowed to proceed overnight while incubated at 37C. Following incubation the 
solution was subjected to cold ethanol precipitation. 1ml of cold ethanol was added to each 
sample and then centrifuged at 10000rpm for 10 minutes which pelleted the peptide 
fractions and left the soluble oligosaccharides in the supernatant. Thus the supernatant was 
removed and dried to completion. 
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Time (Sec)
P
o
te
n
ti
a
l 
(V
) Delay Integration
Cleaning
 
Alpha-1-Acid Glycoprotein (AGP) as a Potential Biomarker for Breast Cancer 211 
Analysis of the enzymatically released oligosaccharides was performed using a DX500™ 
system. Similar to monosaccharide analysis, oligosaccharides are eluted as their oxyanions, 
formed in the highly alkaline environment. Resolution is achieved using a CarboPac PA-100 
column packed with a micro-pellicular resin. The column was equilibrated for 10 minutes 
with 10% 1M sodium hydroxide, 5% 1M sodium acetate and 85% HPLC grade water. 
Following equilibration a linear gradient was developed over 40 minutes to a final eluant 
composition of 10% sodium hydroxide, 20% sodium acetate and 70% water. These 
conditions were maintained for 5 minutes before the column was regenerated for ten 
minutes with 50% sodium hydroxide and 50% water. The pulsed amperometry was 
performed as described for the monosaccharide analysis. 
6. Results 
This investigation studied AGP from 19 breast cancer sufferers with either malignant or 
non malignant forms of breast cancer in term of the monosaccharide composition of the 
oligosaccharide chains and the oligosaccharide fingerprint of the intact chains themselves. 
Under alkaline conditions, the hydroxyl groups of a monosaccharide, either individually 
or as part of a sequence, are ionised to varying degrees such that they exist as negatively 
charged oxyanions. The varying location of the OH groups results in slight differences in 
the pKa value (ranging from 12-14) of individual monosaccharides under these 
conditions. These differences in ionisation, which are unique both with respect to 
individual monosaccharides and also cumulatively in terms of a sequence of 
monosaccharides, can be exploited in chromatographical terms using the anion exchange 
stationary phases and the electrochemical detection (based on pulsed potentials) 
components of high pH anion exchange chromatography (HPAEC). For monosaccharide 
analysis, an alkaline environment of 0.03M sodium hydroxide ionises monosaccharides in 
the hydrolysate and results in the formation of oxyanions unique to individual 
monosaccharides. The interaction of the charged oxyanions with the strong anion-
exchange CarboPac ™ column and the slight differences in relative pKa values aids the 
chromatographic separation of individual monosaccharides. The monosaccharide 
compositions were determined, after acid hydrolysis, using high pH anion exchange 
chromatography (HPAEC). The results obtained are summarised in Table 3 and a typical 
HPAEC profile is shown in Figure 4. 
The monosaccharide composition of the AGP oligosaccharide chains was found to differ 
between normal, non-malignant and malignant groups. Of all the samples containing 
fucose, the malignant breast cancer group displayed the highest average level of this 
monosaccharide compared to the normal and non malignant breast disease group. Only the 
malignant breast cancer population had N-acetylgalactosamine present; this 
monosaccharide is not usually found in AGP and was completely absent from the normal 
samples analysed in the study. The graphs in Figures 5-7 illustrate the statistical significance 
of the fucose and Nacetylgalactosamine composition of AGP with respect to malignancy. 
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Patient Description Galactose* Fucose1 GalNAc1 
1 Benign proliferative breast disease 14.12 1.22 .00 
2 DCIS (+ invasive ductal carcinoma) 15.58 1.78 1.25 
3 Benign proliferative breast disease 14.57 .98 .00 
4 Invasive duct carcinoma 16.22 3.12 2.87 
5 Invasive duct carcinoma 17.33 4.12 3.55 
6 Invasive duct carcinoma 16.47 2.95 1.14 
7 Benign proliferative breast disease 14.29 1.04 .00 
8 Malignant phyllodes tumor. 18.29 4.56 3.22 
9 DCIS (+ invasive ductal carcinoma) 15.98 2.55 .98 
10 Invasive duct carcinoma 17.78 4.01 3.68 
11 Invasive duct carcinoma 17.56 3.93 3.44 
12 Invasive duct carcinoma 19.91 6.02 4.45 
13 Invasive ductal carcinoma 18.84 5.10 4.06 
14 Invasive duct carcinoma 19.76 5.77 4.89 
15 Biphasic fibroepithelial lesion 11.75 .76 .00 
16 Benign proliferative breast disease 13.95 1.31 .00 
17 Invasive duct carcinoma 19.82 5.52 4.36 
18 Invasive duct carcinoma 17.43 4.19 3.49 
19 Invasive duct carcinoma 19.64 5.59 4.80 
* units in mol/mol AGP 
Table 3. The monosaccharide compositions of oligosaccharide chains from AGP, isolated from healthy 
volunteers, patients with non malignant breast cancer and patients with malignant breast cancer, 
determined using high pH anion exchange chromatography  
 
Figure 4. The separation of a mixture of monosaccharides by high pH anion exchange chromatography  
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Figure 5. Fucose Composition of AGP with Respect to Malignancy 
 
Figure 6. N-acetylgalactosamine Composition of AGP with Respect to Malignancy 
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Figure 7. Galactose Composition of AGP with Respect to Malignancy 
The monosaccharides fucose and N-acetylgalactosamine are not normally found on AGP 
oligosaccharide chains; however, both were found to be present in plasma from breast 
cancer patients. Most importantly, the presence of N-acetylgalactosamine appears to 
correlate with the presence of malignancy (Figure 6). While fucose appears to be present in 
small levels in patients with benign proliferative breast disease and in increased levels in 
malignant breast disease (Figure 5), N-acetylgalactosamine appears to be present only in 
ductal carcinoma in-situ (DCIS) and invasive carcinoma. Each AGP molecule has five 
oligosaccharide chains, and each chain can have two, three, or four branches. Given that 
each branch contains a galactose molecule (refer to Figure 1), a higher degree of branching 
can be identified by a higher level of galactose. Therefore, increased galactose levels appear 
to be indicative of increased Malignancy (Figure 7). The AGP oligosaccharide profiles 
differed between the normal, non-malignant and malignant breast cancer groups. 
The flexibility of HPAEC is illustrated by the fact that it also allows the efficient separation 
of oligosaccharide chains on the basis of their size, formal charge, monosaccharide 
composition and intra-chain linkages [49]. A major advantage over other techniques is that 
the HPAEC of oligosaccharides requires no prior derivatisation and can detect to picomole 
sensitivity. The separation of oligosaccharide structures using HPAEC is based primarily on 
the negative charge present on the oligosaccharides due to the presence of terminal sialic 
acid residues. The greater the number of sialic acid residues, the greater the negative charge. 
This leads to a stronger interaction between the oligosaccharide and the resin in the HPAEC 
 
Alpha-1-Acid Glycoprotein (AGP) as a Potential Biomarker for Breast Cancer 215 
analytical column. The application of a sodium acetate gradient causes the displacement of 
oligosaccharides, thus residues with a greater charge require a higher acetate concentration 
to cause displacement. Therefore, for example, a trisialylated oligosaccharide structure is 
retained longer than a bisialylated structure. Thus there is a positive correlation between the 
degree of negative charge and the elution time. Within charge bands, structures can be 
further separated on the basis of size i.e. a biantennary, bisialylated structure will be 
retained less than a triantennary, bisialylated oligosaccharide.  
On a more subtle level the separation of oligosaccharides within each charge band is 
determined by the sequence of monosaccharides which form the chain and also the linkages 
between them. The involvement of hydroxyl groups in glycosidic bonds between 
monosaccharides can alter the charge of the sequence. Therefore oligosaccharides with the 
same monosaccharides but differing in one linkage can be separated using this technique. 
The analysis of oligosaccharides is qualitative, unlike monosaccharide analysis which is both 
qualitative and quantitative, allowing the pattern of oligosaccharides to be determined [49-
50]. The separation of a standard library of the oligosaccharide chains of AGP is shown in 
Figure 8. In the profile, each peak corresponds to a single oligosaccharide chain. The 
sialylated portion of oligosaccharide chains,such as those found in AGP, are separated into 
distinct charge bands based on the number of terminal sialic acids. 
 
Figure 8. A HPAEC separation of a commercially available library of AGP oligosaccharides illustrating 
their separation into charged bands based on the number of sialic acid residues present at the chain 
terminus. 
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The greater the number of sialic acids, the greater the overall negative charge resulting in a 
longer retention time. Typically bisialylated oligosaccharides elute between 20 and 30 
minutes; trisialylated, 30 to 40 minutes and tetrasialylated 40-50 minutes (Figure 8). The 
oligosaccharide profiles for the AGP oligosaccharides from the clinical samples analysed in 
this study are shown in Figure 9. 
 
Figure 9. Representative oligosaccharide profiles of AGP, isolated from healthy volunteers (purple 
line), non malignant breast cancer (green line), malignant breast cancer (red line) were separated using 
high pH anion exchange chromatography and compared with a standard library of AGP 
oligosaccharides (black line). 
The oligosaccharide profiles of AGP oligosaccharides from healthy volunteers, non 
malignant breast cancer and malignant breast cancer are comparable with the standard 
library (Figure 8) in that they both display peaks in the bi-, tri- and tetra-sialylated regions. 
Although qualitatively similar, the profiles for the breast cancer populations are noticeable 
for the earlier elution of the comparable peak regions. This reduction in retention is 
indicative of the presence of fucose on the oligosaccharide chains [49-50] which reinforces 
the results of the monosaccharide compositional analysis. Additionally, the two cancer 
populations appear to have fewer tetra-sialylated chains (elute 40-50 minutes) even if the 
presence of fucosylation is taken into account.  
7. Further research 
The oligosaccharide chains of each AGP in this study were released and analysed by high 
pH anion exchange chromatography [Figure 8] and showed differences that could be 
diagnostic and the basis of future research. Monosaccharide compositional analysis using 
HPAEC has highlighted the differences that exist between normal and breast disease 
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populations. Specifically the presence of fucose, galactose and N-acetylgalactosamine 
appears to be correlated with breast cancer malignancy. The presence of N-
acetylgalactosamine in the malignant population, together with its absence from the healthy 
and non-malignant populations suggests that the modification could form the basis of a 
serum biomarker for breast cancer malignancy with potential prognostic utility. HPAEC 
also provides useful information about the oligosaccharide structures present on AGP and 
allows the development of an oligosaccharide ‘fingerprint’ for each cohort of breast cancer 
patients.  
8. Conclusion 
Glycosylated molecules play major roles in oncogenesis, but their potential as cancer 
biomarkers remains unclear. Historically the reasons were twofold. Firstly, the large 
heterogeneity of structures arising from the cellular biosynthesis of glycans were not able to 
be detected and resolved by the analytical technology available at that point in time. 
Secondly the definitive diagnosis of cancerous disease normally required invasive 
techniques. These two hindrances have been addressed through the development of 
techniques such as high pH anion exchange chromatography (HPAEC) which now allows 
the sensitive (to picomole level) determination of glycosylated structures including linkage 
isomers of oligosaccharide chains. The solution to the second problem could lie in the 
development of tests based on the presence, in biological fluids, of glycosylated molecules 
which are disease-specific markers.  
Alpha-1-acid glycoprotein is a prominent example of a molecule in which alterations in the 
structure of the surface oligosaccharides has provided some potential in the diagnosis and 
prognosis of physiological and pathophysiological conditions and determination of the 
effectiveness of treatments. There have been a vast number of studies concerned with 
quantifying the levels and characterising the microheterogeneity of AGP in a number of 
diseases [Reviewed in 7-9]. Variation in the branching of the chains, levels of fucose, sialic 
acid and the presence or absence of antigens such as sialyl Lewis X are commonly reported 
and represent the potential exploitation of AGP heterogeneity as prognostic and diagnostic 
markers of disease [7]. 
In spite of major advances in detection and treatment, deaths from breast cancer are still 
high therefore there is a very definite requirement for the identification of a breast cancer 
specific biomarker to indicate the onset of the disease. Breast cancer is the most common 
cancer in women and currently diagnosis is reliant upon mammography and invasive 
techniques such as biopsy. There is no serum biomarker currently used in clinical practice 
for the detection and diagnosis of breast cancer. The discovery of a breast cancer-specific 
biomarker whose presence and/or altered expression in the serum precedes  
the appearance of a malignant mass would allow the development of a non-invasive 
serologic test and provide an invaluable screening tool in the assessment of high risk 
individuals. 
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The current study has identified that the quantitative and qualitative changes in AGP 
glycosylation observed among patients with malignant and non malignant breast cancer 
may in fact, provide the basis of a serum biomarker with potential prognostic utility. The 
monosaccharide and oligosaccharide composition of the AGP glycosylation was found to 
differ between normal, non-invasive and invasive groups. From our results, fucose, N-
acetylgalactosamine and galactose could be used as a screening test for early detection of 
breast cancer, and also as markers of breast carcinoma progression or “tumour load”, as 
changes in the levels of the substances correlate with disease progression. Most importantly, 
N-acetylgalactosamine could be used as a marker for the presence of malignancy in the 
breast, as N-acetylgalactosamine is present only in the plasma of patients with malignant 
breast lesions. The implications of the use of N-acetylgalactosamine as a marker for the 
presence of breast malignancy is profound; a definite diagnosis of breast carcinoma could be 
carried out by simple blood tests.  
The current standard method of diagnosing early stages of breast cancer is mammography 
which, along with other imaging technology, requires expensive instrumentation. The use of 
blood tests to diagnose breast cancer would obviously have numerous advantages over 
mammography, and would prove to be an invaluable tool in the fight against breast cancer. 
The use of blood tests based on differences in AGP glycosylation for diagnosing breast 
cancer could be done inexpensively using ELISA. Mammography requires radiologists to 
review images, while screening for AGP markers can be performed by laboratory 
technicians with a high degree of automation. Mammography suffers from a relatively high 
degree of false diagnoses, while screening for N-acetylgalactosamine appears to diagnose 
breast cancer with 100% accuracy. Breast cancer has a high rate of survival if it is detected in 
its early stages. Unfortunately, large segments of the at-risk female population do not 
receive mammograms regularly, as a result of lack of access to mammography facilities, 
high cost, discomfort caused by the procedure, and potential or perceived risks of radiation 
exposure. The factors preventing women from receiving mammograms regularly would not 
be present with blood tests. Small blood samples could be taken from patients with minimal 
discomfort and cost in local medical centres. These samples could then be sent to large, 
centralised testing facilities for processing. The improved accessibility and convenience of 
this strategy over mammography would result in a greater segment of the at-risk female 
population receiving regular breast cancer screening, which would result in more early 
diagnoses, and therefore higher survival rates.  
The use of blood tests that employ AGP alterations as markers of breast cancer has obvious 
commercial applications. These blood tests would likely become routine diagnostic 
procedures like the prostate-specific antigen (PSA) test. The potential market value of a 
breast cancer blood test would be comparable to that of the PSA test, which is about $1.5 
billion (USD) per year in the United States alone. Clearly, on an international scale, blood 
tests for diagnosing breast cancer would have a huge market value. In the event that AGP 
alterations are found to be markers of other cancers, the international market value of AGP-
based blood tests would likely double or triple, reaching as high as $20 billion (USD) per 
year.  
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